Trading Options with an Edge
Select Page

Unusual Large Call Buy in Potential Breast Cancer Winner into Q4 Readout

Unusual Large Call Buy in Potential Breast Cancer Winner into Q4 Readout

by | Nov 18, 2021 | Flow Alerts

Olema Oncology (OLMA) jumps here with an unusual buy of 3100 December $30 calls for $4. OLMA is a $1B Biotech discovering therapies for women’s cancers. Olema’s lead product OP-1250 has the potential to emerge as a backbone therapy for breast cancer. Peak sales for OP-1250 could be $3B to $5B or higher according to Jefferies. Approval is likely a long way off with 2027 estimated. OLMA has a presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer planned for Q4 2021